Angela Velez, MD
Clinical Neurophysiology · San Antonio, TXNPI 1558558809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 398 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 398 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$743
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$724
- Takeda Pharmaceuticals U.S.A., Inc.$703
- Sunovion Pharmaceuticals Inc.$437
- Alkermes, Inc.$402
- plus $3K from 24 others
What the payments were for
- Food & beverage$6,83798%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,308 |
| Otsuka America Pharmaceutical, Inc. | 53 | $743 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $724 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $703 |
| Sunovion Pharmaceuticals Inc. | 27 | $437 |
| Alkermes, Inc. | 19 | $402 |
| Lundbeck LLC | 22 | $387 |
| Almatica Pharma LLC | 17 | $366 |
| Ironshore Pharmaceuticals Inc. | 15 | $299 |
| Tris Pharma Inc | 11 | $247 |
| Vanda Pharmaceuticals Inc. | 13 | $229 |
| Corium, LLC | 12 | $221 |
| Johnson & Johnson | 7 | $183 |
| Supernus Pharmaceuticals, Inc. | 5 | $96 |
| Avanir Pharmaceuticals, Inc. | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| Biogen | 1 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Bausch Health US, LLC | 3 | $47 |
| Adlon Therapeutics L.p. | 2 | $40 |
| Neos Therapeutics, LP | 2 | $38 |
| Neuronetics, Inc. | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Brainsway USA Inc | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$6,962 in reported general payments places this provider in the 70th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 15 | $21,722 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 70 | $3,383 |
| Lisdexamfetamine Dimesylate | 16 | $3,124 |
| Asenapine Maleate | 20 | $1,633 |
| Duloxetine Hcl | 99 | $1,569 |
| Bupropion XlBupropion Hcl | 60 | $1,164 |
| Doxepin Hcl | 31 | $932 |
| Trazodone Hcl | 67 | $856 |
| Aripiprazole | 49 | $850 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $809 |
| Sertraline Hcl | 49 | $747 |
| Escitalopram Oxalate | 60 | $617 |
| Quetiapine Fumarate | 40 | $583 |
| Clonazepam | 111 | $553 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $743 | $21,72215 claims |
| Almatica Pharma LLCSertraline Hcl | $366 | $74749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in San Antonio
- Jose CavazosSan Antonio$1K
- Kameel KarkarSan Antonio$616
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Kalarickal OommenLubbock$48K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Rony NinanPearland$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.